Recombinant Platelet Factor 4 for Heparin Neutralization

Protamine sulfate has been used for many years to reverse the effects of unfractionated heparin, but it can cause hemodynamic changes and other serious side effects. Platelet factor 4 (PF4) is a naturally occurring protein synthesized in megakaryocytes and eventually stored in the α granules of platelets for later release. Although the complete physiologic role of PF4 is unknown, it is highly effective for the neutralization of heparin anticoagulation. Several preliminary animal studies and trials using blood obtained from cardiopulmonary bypass circuits suggested recombinant PF4 (rPF4) would be an effective alternative to protamine. In the first open-label, phase 1 human study, patients received rPF4 in doses of 0.5, 1.0, 2.5, or 5.0 mg/kg over 3 minutes to reverse heparin anticoagulation after diagnostic cardiac catheterization. There were no important hemodynamic changes and the rPF4 was highly effective in neutralizing heparin. Serial measurements of rPF4 levels showed a monophasic elimination pattern with a serum half-life of 25.5 ± 13.5 minutes that was independent of dose administered. A randomized and blinded trial comparing rPF4 to protamine confirmed the safety and effectiveness of rPF4. Although rPF4 was initially being evaluated as a clinical alternative to protamine, it is not currently being developed for general clinical use.

KEYWORDS

Heparin - platelet factor 4 - protamine - anticoagulation

REFERENCES

• 1 Weiss M E, Adkinson Jr N F. Allergy to protamine.  Clin Rev Allergy. 1991;  9 339-355
• 2 Porsche R, Brenner Z R. Allergy to protamine sulfate.  Heart Lung. 1999;  28 418-428
• 3 Lowenstein E, Johnston W E, Lappas D G et al.. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin.  Anesthesiology. 1983;  59 470-473
• 4 Holland C L, Singh A K, McMaster P RB, Fang W. Adverse reactions to protamine sulfate following cardiac surgery.  Clin Cardiol. 1984;  7 157-162
• 5 Moorthy S S, Pond W, Rowland R G. Severe circulatory shock following protamine (an anaphylactic reaction).  Anesth Analg. 1980;  59 77-78
• 6 Jackson D R. Sustained hypotension secondary to protamine sulfate.  Angiology. 1970;  21 295-298
• 7 Olinger G N, Becker R M, Bonchek L I. Noncardiogenic pulmonary edema and peripheral vascular collapse following cardiopulmonary bypass: rare protamine reaction?.  Ann Thorac Surg. 1980;  29 20-25
• 8 Nordstrom L, Fletcher R, Pavek K. Shock of anaphylactoid type induced by protamine: a continuous cardiorespiratory record.  Acta Anaesthesiol Scand. 1978;  22 195-201
• 9 Stewart W J, McSweeney S M, Kellett M R, Faxon D P, Ryan T J. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.  Circulation. 1984;  70 788-792
• 10 Levy J H, Zaidan J R, Faraj B. Prospective evaluation of the risk for protamine reactions in patients with NPH insulin dependent diabetes.  Anesth Analg. 1986;  65 739-742
• 11 Levy J H, Schwieger I M, Ziadan J. Evaluation of patients at risk for protamine reactions.  J Thorac Cardiovasc Surg. 1989;  98 200-204
• 12 Weiss M E, Nyhan D, Peng Z et al.. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine.  N Engl J Med. 1989;  320 886-892
• 13 Horrow J C. Protamine: a review of its toxicity.  Anesth Analg. 1985;  64 348-361
• 14 Hird R B, Wakefield T W, Mukherjee R et al.. Direct effects of protamine sulphate on myocyte contractile processes. Cellular and molecular mechanisms.  Circulation. 1995;  92(9 suppl) II433-II445
• 15 O S J, Cox M H, Mukherjee R, Clair M J, Crawford Jr F A, Spinale F G. Direct and interactive effects of cardioplegic arrest and protamine on myocyte contractility.  Ann Thorac Surg. 1996;  62 489-494
• 16 Cavarocchi N C, Schaff H V, Orszulak T, Homburger H A, Schnell Jr W A, Pluth J R. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass.  Surgery. 1985;  98 525-531
• 17 Carr J A, Silverman N. The heparin-protamine interaction. A review.  J Cardiovasc Surg. 1999;  40 659-666
• 18 Sugi K, Esato K. Effect of thromboxane synthetase inhibitor on protamine-induced circulatory changes in sheep.  Surgery. 1993;  114 586-590
• 19 Li J M, Hajarizadeh H, LaRosa C, Rohr M J, Vander Salm T J, Cutler B S. Heparin and protamine stimulates the production of nitric oxide.  J Cardiovasc Surg (Torino). 1996;  37 445-452
• 20 Weiss W A, Gilman J, Catenaci A, Osterberg A. Heparin neutralization with Polybrene administered intravenously.  JAMA. 1958;  166 603-607
• 21 Haller J A, Ransdell H T, Stowens D, Rubel W F. Renal toxicity of polybrene in open-heart surgery.  J Thorac Cardiovasc Surg. 1962;  44 486-493
• 22 Deuel T F, Keim P S, Farmer M, Henrikson R L. Platelet factor 4: complete amino acid sequence.  Proc Natl Acad Sci USA. 1977;  74 2256-2258
• 23 Walz D A, Wu V Y, DeLamo R, Dene H, McCoy L E. Primary structure of human platelet factor 4.  Thromb Res. 1977;  11 893-898
• 24 Kaplan K L, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo.  Blood. 1981;  57 199-202
• 25 Nichols A B, Owen J, Kaplan K L, Sciacca R R, Cannon P J, Nossel H L. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary artery disease.  Blood. 1982;  60 650-654
• 26 Levine S P, Suarez A J, Sorenson R R, Raymond P M, Knieriem L K. Platelet factor 4 release during exercise in patients with coronary artery disease.  Am J Hematol. 1984;  17 117-127
• 27 Sadayasu T, Nakashima Y, Yashiro A, Kawashima T, Kuroiwa A. Heparin-releasable platelet factor 4 in patients with coronary artery disease.  Clin Cardiol. 1991;  14 725-729
• 28 Cella G, Colby S I, Taylor A D, McCracken L, Parisi A F, Sasahara A A. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.  Thromb Res. 1983;  29 499-509
• 29 Maione T E, Gray G S, Petro J et al.. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.  Science. 1990;  247 77-79
• 30 Deuel T F, Senior R M, Chang D, Griffin G L, Heinrikson R L, Kaiser E T. Platelet factor 4 is chemotactic for neutrophils and monocytes.  Proc Natl Acad Sci USA. 1981;  78 4584-4587
• 31 Gewirtz A M, Calabretta B, Rucinski B, Niewiarowski S, Xu W Y. Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.  J Clin Invest. 1989;  83 1477-1486
• 32 Han Z C, Sensebe L, Abgrall J F, Briere J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro.  Blood. 1990;  75 1234-1239
• 33 Barone A D, Ghrayeb J, Hammerling U, Zucker M B, Thorbecke G J. The expression in E. coli of recombinant human platelet factor 4, a protein with immunoregulatory activity.  J Biol Chem. 1988;  263 8710-8714
• 34 Handin R I, Cohen H J. Purification and binding properties of human platelet factor four.  J Biol Chem. 1976;  251 4273-4282
• 35 Myers J A, Gray G S, Peters D J et al.. Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein.  Protein Expr Purif. 1991;  2 136-143
• 36 Cook J J, Niewiarowski S, Yan Z et al.. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.  Circulation. 1992;  85 1102-1109
• 37 Kelton J G, Smith J W, Warkentin T E, Hayward C P, Denome G A, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.  Blood. 1994;  83 3232-3239
• 38 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexes with heparin or bound to endothelial cells.  J Clin Invest. 1994;  93 81-88
• 39 Korutla L N, Stewart G J, Lasz E C, Maione T E, Niewiarowski S. Evaluation of recombinant platelet factor 4 and protamine sulfate for heparin neutralization: clotting and clearance studies in rat.  Thromb Haemost. 1994;  71 609-614
• 40 Cobel-Geard R J, Hassouna H I. Interaction of protamine sulfate with thrombin.  Am J Hematol. 1983;  14 227-233
• 41 Bernabei A, Gikakis N, Maione T E et al.. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1995;  109 765-771
• 42 Williams R D, D’Ambra M N, Maione T E, Lynch K E, Keene D F. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood.  J Thorac Cardiovasc Surg. 1994;  108 975-983
• 43 Levy J H, Cormack J G, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine.  Anesth Analg. 1995;  81 35-37
• 44 Dehmer G J, Fisher M, Tate D A, Teo S, Bonnem E M. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans.  Circulation. 1995;  91 2188-2194
• 45 Dehmer G J, Lange R A, Tate D A et al.. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.  Circulation. 1996;  94(9 suppl) II347-II352
• 46 Baim D S, Grossman W. Complications of cardiac catheterization. In: Baim DS, Grossman W Grossman’s Cardiac Catheterization, Angiography, and Intervention. 6th ed. Philadelphia; Lippincott Williams & Wilkins 2000: 35-68
• 47 Sasisekharan R, Bulmer M, Moreman K W, Cooney C L, Langer R. Cloning and expression of heparinase I gene from Flavobacterium heparinum .  Proc Natl Acad Sci USA. 1993;  90 3660-3664
• 48 Michelsen L G, Kikura M, Levy J H et al.. Heparinase I (Neutralase^™) reversal of systemic anticoagulation.  Anesthesiology. 1996;  85 339-346
• 49 Heres E K, Horrow J C, Gravlee G P et al.. A dose-determining trial of heparinase-I (Neutralase^™) for heparin neutralization in coronary artery surgery.  Anesth Analg. 2001;  93 1446-1452